Investing.com - Financial Markets Worldwide

Adaptimmune stock plunges after announcing Nasdaq delisting plans

Published 20/10/2025, 14:20
© Reuters.
ADAP
-70.46%

Investing.com -- Adaptimmune Therapeutics Plc (NASDAQ:ADAP) stock plummeted 62.5% in premarket trading Monday after the company announced plans to voluntarily delist from the Nasdaq Capital Market and deregister its securities under the Exchange Act.

The cell therapy company said its Board of Directors authorized the delisting decision on October 15, with trading of its American Depositary Shares expected to be suspended after market close on or around October 27. Adaptimmune plans to file the necessary Form 25 with the SEC on or about October 28 to formalize the delisting process.

CEO Adrian Rawcliffe explained the move follows the company’s recent transaction with US WorldMeds and ongoing restructuring efforts. "The delisting from Nasdaq and deregistration should facilitate cost reductions and further support our goal to maximize value going forward," Rawcliffe stated.

The decision comes after Adaptimmune received notice from Nasdaq on September 22 that it had until December 1 to regain compliance with the exchange’s minimum bid price requirement of $1.00 per share.

Following delisting, the company expects its shares may trade on the OTC Pink Limited Market, though it acknowledged there’s "no guarantee" that broker support or trading will continue. Adaptimmune intends to file a Form 15 with the SEC after delisting to suspend its reporting obligations, citing fewer than 300 shareholders of record.

The Board determined that "the burdens associated with operating as a registered public company listed on Nasdaq outweigh any advantages," pointing to significant costs related to SEC filings, legal and audit expenses, and management time demands under various regulatory requirements.

Adaptimmune completed its transaction with US WorldMeds on July 31 and continues efforts to maximize value from its remaining assets, including programs targeting PRAME and CD70.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.